Kamada Stock

Kamada ROA

The Return on Assets (ROA) of Kamada (KMDA) as of Sep 15, 2026 is 5.33 %. In the previous year, Return on Assets (ROA) was 3.88 % — a change of 37.25% (higher).

ROA

5.33 %

YoY

37.25%

Last updated:

In 2026, Kamada's return on assets (ROA) was 5.33 %, a 37.25% increase from the 3.88 % ROA in the previous year.

The Kamada ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
16.14 USD
Jan 1, 2019
12.80 USD
Jan 1, 2020
8.14 USD
Jan 1, 2021
-0.70 USD
Jan 1, 2022
-0.72 USD
Jan 1, 2023
2.33 USD
Jan 1, 2024
3.88 USD
Jan 1, 2025
5.33 USD
The Kamada ROA history
YEARROAYoY
5.33 %+37.25%
3.88 %+66.44%
2.33 %-424.20%
-0.72 %+2.88%
-0.70 %-108.60%
8.14 %-36.45%
12.80 %-20.69%
16.14 %+185.64%
5.65 %-183.68%
-6.75 %-38.88%
-11.05 %+4.60%
-10.56 %
Access this data via the Eulerpool API

Kamada Stock analysis

What does Kamada do? Kamada Ltd is an Israel-based company specializing in the development and marketing of biopharmaceutical products for humans and animals. The company was founded in 1990 by a team of experienced executives and scientists from the biotech industry. Since its inception, Kamada has become a global leader in plasma fractionation and the production of antibodies and enzymes. The company is listed on the NASDAQ and the Tel Aviv Stock Exchange and has over 450 employees in its facilities in Israel and the USA. Kamada's business model is based on combining innovative science and technology to develop products and therapies for rare and severe diseases. The company is constantly working to improve its production processes to deliver more efficient and cost-effective products. Kamada operates in three divisions: human therapeutics, veterinary medicine, and plasma research. The human therapeutics division develops and markets products for the treatment of diseases such as alpha-1 antitrypsin deficiency, immunoglobulin deficiency, hemophilia, and other serious conditions. The veterinary medicine division offers products for the treatment of diseases in dogs, horses, and cows to veterinary professionals. The plasma research division focuses on developing technologies for the production of plasma derivatives and discovering new applications for plasma proteins. Kamada has a wide range of products on the market, including its flagship product Glassia, which is used to treat alpha-1 antitrypsin deficiency, a rare genetic disease that can affect the lungs. The company also produces intravenous immunoglobulin preparations for the treatment of immune deficiencies and other immune system disorders, as well as recombinant factor VIII for the treatment of hemophilia. In veterinary medicine, Kamada offers products such as Equine Seramune, designed for horses and used to treat life-threatening infections caused by bacteria found in the intestines of horses. The company also produces products for the treatment of mastitis, an infection of the milk ducts in cows, and gastrointestinal tract infections in dogs. Kamada takes pride in playing a leading role in plasma research and technology. The company's research has resulted in groundbreaking technologies that allow for the faster and more cost-effective production of important plasma proteins than was previously possible. Kamada works closely with other research institutions and companies to collaborate on solutions for severe and rare diseases. Over the years, Kamada has received numerous awards and recognition for its groundbreaking research and development work. The company is committed to continuing to develop innovative products and therapies to improve the lives of patients with rare and severe diseases. Overall, Kamada Ltd has experienced remarkable growth in recent years. It is a company that plays a leading role in the market for biopharmaceutical products based on top-notch scientific research and efficient technology. In the future, Kamada will undoubtedly continue to develop groundbreaking products and therapies to improve the lives of patients worldwide. Kamada is one of the most popular companies on Eulerpool.

ROA Details

Understanding Kamada's Return on Assets (ROA)

Kamada's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Kamada's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Kamada's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Kamada’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Kamada stock

Return on Assets (ROA) of Kamada is 5.33 % in 2026.

Return on Assets (ROA) of Kamada changed from 3.88 % to 5.33 %, representing a 37.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Kamada since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Kamada with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

Profitability — Kamada

All Key Metrics — Kamada